​
​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences stock forecast is as follows: an average price target of $81.77 (represents a -7.50% downside from GILD’s last price of $88.40) and a rating consensus of 'Buy', based on 23 wall street analysts offering a 1-year stock forecast.

GILD Price Target

The average price target for Gilead Sciences (GILD) is $81.77 based on 1-year price targets from 23 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $54.00. This represents a potential -7.50% downside from GILD's last price of $88.40.

GILD Analyst Ratings

Buy

According to 23 Wall Street analysts, Gilead Sciences's rating consensus is 'Buy'. The analyst rating breakdown for GILD stock is 0 'Strong Buy' (0.00%), 15 'Buy' (65.22%), 7 'Hold' (30.43%), 1 'Sell' (4.35%), and 0 'Strong Sell' (0.00%).

Gilead Sciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Joseph CatanzaroPiper Sandler$105.00$90.0916.55%18.78%
Oct 21, 2024Evan David SeigermanBMO Capital$94.00$86.119.16%6.33%
Oct 21, 2024Andrew BerensLeerink Partners$96.00$86.7210.70%8.60%
Oct 18, 2024Terence FlynnMorgan Stanley$84.00$87.07-3.53%-4.98%
Sep 23, 2024Michael YeeJefferies$95.00$83.7613.42%7.47%
Sep 12, 2024Salveen RichterGoldman Sachs$71.00$82.85-14.30%-19.68%
Sep 12, 2024Terence FlynnMorgan Stanley$79.00$82.63-4.39%-10.63%
Sep 11, 2024Joseph CatanzaroPiper Sandler$95.00$79.9318.85%7.47%
Aug 14, 2024Asthika GoonewardeneTruist Financial$83.00$74.1411.95%-6.11%
Aug 09, 2024Evan David SeigermanBMO Capital$85.00$75.5912.45%-3.85%
Row per page
Go to

The latest Gilead Sciences stock forecast, released on Nov 07, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $105.00, which represents a 16.55% increase from the stock price at the time of the forecast ($90.09), and a 18.78% increase from GILD last price ($88.40).

Gilead Sciences Price Target by Period

1M3M12M
# Anlaysts4819
Avg Price Target$94.75$89.88$84.53
Last Closing Price$88.40$88.40$88.40
Upside/Downside7.18%1.67%-4.38%

In the current month, the average price target of Gilead Sciences stock is $94.75, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 7.18% increase as opposed to Gilead Sciences's last price of $88.40. This month's average price target is up 5.42% compared to last quarter, and up 12.09% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024Citigroup-BuyInitialise
Oct 21, 2024BarclaysOverweightOverweightHold
Oct 21, 2024BernsteinOutperformOutperformHold
Oct 21, 2024Leerink PartnersOverweightOverweightHold
Oct 21, 2024Wells FargoSector PerformSector PerformHold
Oct 21, 2024RBC CapitalUnderperformUnderperformHold
Oct 21, 2024Leerink Partners-OutperformUpgrade
Oct 18, 2024Cowen & Co.BuyBuyHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 17, 2024Bernstein-OutperformInitialise
Row per page
Go to

Gilead Sciences's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its GILD rating from "null" to "Buy".

Gilead Sciences Financial Forecast

Gilead Sciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$7.12B$7.05B$6.60B$6.35B$7.39B$7.04B$6.26B$6.59B$7.24B$7.42B$6.22B$6.42B$7.42B$6.58B$5.14B$5.55B$5.88B$5.60B$5.68B$5.28B$5.09B$6.50B
Avg Forecast$7.50B$7.30B$6.85B$6.64B$7.16B$7.02B$6.70B$6.36B$7.10B$6.81B$6.45B$6.33B$6.64B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$5.74B$6.65B
High Forecast$7.77B$7.56B$7.10B$6.73B$7.44B$7.05B$6.70B$6.36B$7.27B$7.02B$6.69B$6.56B$6.87B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$6.89B$7.98B
Low Forecast$7.29B$7.09B$6.66B$6.55B$6.96B$6.98B$6.70B$6.36B$6.89B$6.63B$6.27B$6.15B$6.45B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$4.59B$5.32B
# Analysts33351379910211010139916101019131015998812161915
Surprise %--------1.00%1.04%1.02%1.00%1.11%1.15%1.07%1.05%1.10%1.18%1.02%0.95%1.05%1.05%0.97%1.02%1.03%1.00%1.03%1.00%0.89%0.98%

Gilead Sciences's average Quarter revenue forecast for Mar 24 based on 9 analysts is $6.36B, with a low forecast of $6.36B, and a high forecast of $6.36B. GILD's average Quarter revenue forecast represents a -10.65% decrease compared to the company's last Quarter revenue of $7.12B (Dec 23).

Gilead Sciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351379910211010139916101019131015998812161915
EBITDA--------$1.61B$2.62B$1.67B$2.01B$2.42B$3.11B$2.08B$86.00M$1.53B$4.23B$2.69B$3.06B$2.57B$2.59B$2.14B$2.59B$2.49B$-904.00M$3.01B$2.96B$2.68B$4.17B
Avg Forecast$2.45B$2.38B$2.23B$2.16B$2.33B$2.29B$2.19B$619.71M$2.32B$2.22B$2.10B$563.37M$2.38B$2.18B$2.08B$512.15M$2.35B$2.24B$2.16B$3.02B$2.52B$2.23B$1.88B$2.44B$2.03B$1.99B$1.97B$2.69B$2.98B$4.27B
High Forecast$2.53B$2.47B$2.31B$2.19B$2.43B$2.30B$2.19B$743.65M$2.37B$2.29B$2.18B$676.04M$2.86B$2.18B$2.08B$614.59M$2.35B$2.24B$2.16B$3.62B$2.52B$2.23B$1.88B$2.93B$2.03B$1.99B$1.97B$3.23B$3.58B$5.12B
Low Forecast$2.38B$2.31B$2.17B$2.14B$2.27B$2.28B$2.19B$495.77M$2.25B$2.16B$2.04B$450.70M$1.91B$2.18B$2.08B$409.72M$2.35B$2.24B$2.16B$2.41B$2.52B$2.23B$1.88B$1.95B$2.03B$1.99B$1.97B$2.15B$2.39B$3.41B
Surprise %--------0.70%1.18%0.79%3.57%1.01%1.43%1.00%0.17%0.65%1.89%1.24%1.01%1.02%1.16%1.14%1.06%1.23%-0.45%1.53%1.10%0.90%0.98%

9 analysts predict GILD's average Quarter EBITDA for Mar 24 to be $619.71M, with a high of $743.65M and a low of $495.77M. This is -61.56% lower than Gilead Sciences's previous annual EBITDA (Dec 23) of $1.61B.

Gilead Sciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351379910211010139916101019131015998812161915
Net Income--------$1.43B$2.18B$2.14B$1.01B$1.64B$1.79B$1.14B$12.00M$376.00M$2.59B$1.52B$1.73B$1.55B$360.00M$-3.35B$1.55B$2.70B$-1.17B$1.88B$1.98B$1.54B$2.70B
Avg Forecast$2.60B$2.57B$2.28B$2.19B$2.14B$1.92B$2.02B$19.05M$2.21B$2.40B$2.06B$17.32M$592.24M$1.78B$1.90B$15.75M$1.99B$2.20B$2.18B$1.74B$2.55B$2.44B$1.81B$1.45B$2.09B$2.18B$2.15B$1.79B$1.71B$2.76B
High Forecast$2.72B$2.69B$2.39B$2.27B$2.60B$1.96B$2.02B$22.86M$2.56B$2.62B$2.16B$20.78M$710.69M$1.78B$1.90B$18.90M$1.99B$2.20B$2.18B$2.08B$2.55B$2.44B$1.81B$1.74B$2.09B$2.18B$2.15B$2.15B$2.06B$3.31B
Low Forecast$2.50B$2.48B$2.19B$2.13B$1.48B$1.88B$2.01B$15.24M$1.99B$2.15B$1.98B$13.86M$473.80M$1.78B$1.90B$12.60M$1.99B$2.20B$2.18B$1.39B$2.55B$2.44B$1.81B$1.16B$2.09B$2.18B$2.15B$1.43B$1.37B$2.21B
Surprise %--------0.65%0.91%1.04%58.31%2.77%1.00%0.60%0.76%0.19%1.18%0.70%1.00%0.61%0.15%-1.85%1.07%1.29%-0.54%0.87%1.10%0.90%0.98%

Gilead Sciences's average Quarter net income forecast for Mar 24 is $19.05M, with a range of $15.24M to $22.86M. GILD's average Quarter net income forecast represents a -98.67% decrease compared to the company's last Quarter net income of $1.43B (Dec 23).

Gilead Sciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351379910211010139916101019131015998812161915
SG&A--------$1.61B$1.31B$1.85B$1.32B$2.02B$1.21B$1.36B$1.08B$1.65B$1.19B$1.35B$1.05B$1.73B$1.11B$1.24B$1.08B$1.20B$1.05B$1.09B$1.03B$997.00M$850.00M
Avg Forecast$1.54B$1.50B$1.41B$1.36B$1.47B$1.44B$1.38B$1.09B$1.46B$1.40B$1.33B$987.27M$2.56B$1.26B$1.20B$897.51M$1.36B$1.29B$1.25B$1.06B$1.45B$1.29B$1.09B$1.01B$1.17B$1.15B$1.14B$934.04M$1.11B$868.64M
High Forecast$1.60B$1.56B$1.46B$1.38B$1.53B$1.45B$1.38B$1.30B$1.50B$1.44B$1.38B$1.18B$3.07B$1.26B$1.20B$1.08B$1.36B$1.29B$1.25B$1.27B$1.45B$1.29B$1.09B$1.21B$1.17B$1.15B$1.14B$1.12B$1.33B$1.04B
Low Forecast$1.50B$1.46B$1.37B$1.35B$1.43B$1.44B$1.38B$868.79M$1.42B$1.36B$1.29B$789.81M$2.05B$1.26B$1.20B$718.01M$1.36B$1.29B$1.25B$848.04M$1.45B$1.29B$1.09B$806.32M$1.17B$1.15B$1.14B$747.23M$888.34M$694.91M
Surprise %--------1.10%0.94%1.39%1.34%0.79%0.96%1.13%1.21%1.21%0.92%1.08%1.00%1.19%0.86%1.14%1.07%1.03%0.91%0.96%1.10%0.90%0.98%

Gilead Sciences's average Quarter SG&A projection for Mar 24 is $1.09B, based on 9 Wall Street analysts, with a range of $868.79M to $1.30B. The forecast indicates a -32.46% fall compared to GILD last annual SG&A of $1.61B (Dec 23).

Gilead Sciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351379910211010139916101019131015998812161915
EPS--------$1.15$1.75$1.71$0.81$1.31$1.43$0.91$0.01$0.30$2.06$1.21$1.38$1.24$0.29$-2.67$1.23$2.13$-0.92$1.48$1.55$1.18$2.07
Avg Forecast$2.07$2.05$1.82$1.75$1.71$1.53$1.61$-1.49$1.76$1.92$1.64$1.52$1.52$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$1.86$2.33
High Forecast$2.17$2.15$1.90$1.81$2.07$1.56$1.61$-1.44$2.04$2.09$1.72$1.57$1.59$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$2.23$2.80
Low Forecast$1.99$1.97$1.75$1.70$1.18$1.50$1.61$-1.56$1.59$1.72$1.58$1.48$1.46$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$1.49$1.86
Surprise %--------0.65%0.91%1.04%0.53%0.86%1.00%0.60%0.01%0.19%1.17%0.70%0.66%0.61%0.15%-1.85%0.78%1.28%-0.53%0.86%0.96%0.63%0.89%

According to 9 Wall Street analysts, Gilead Sciences's projected average Quarter EPS for Mar 24 is $-1.49, with a low estimate of $-1.56 and a high estimate of $-1.44. This represents a -229.84% decrease compared to GILD previous annual EPS of $1.15 (Dec 23).

Gilead Sciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer$24.80$44.7680.48%Hold
MRKMerck$96.31$128.8933.83%Buy
AZNAstraZeneca$63.23$84.0032.85%Buy
BMYBristol-Myers Squibb Company$56.22$65.5016.51%Hold
JNJJohnson & Johnson$154.00$179.1316.32%Buy
AMGNAmgen$283.61$301.816.42%Buy
ABBVAbbVie$164.99$173.305.04%Buy
LLYEli Lilly and Company$746.20$778.104.27%Buy
GILDGilead Sciences$88.40$81.77-7.50%Buy

GILD Forecast FAQ

Is Gilead Sciences a good buy?

Yes, according to 23 Wall Street analysts, Gilead Sciences (GILD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 65.22% of GILD's total ratings.

What is GILD's price target?

Gilead Sciences (GILD) average price target is $81.77 with a range of $54 to $105, implying a -7.50% from its last price of $88.4. The data is based on 23 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Gilead Sciences stock go up soon?

According to Wall Street analysts' prediction for GILD stock, the company can go down by -7.50% (from the last price of $88.4 to the average price target of $81.77), up by 18.78% based on the highest stock price target, and down by -38.91% based on the lowest stock price target.

Can Gilead Sciences stock reach $130?

GILD's average twelve months analyst stock price target of $81.77 does not support the claim that Gilead Sciences can reach $130 in the near future.

What is Gilead Sciences's current price target trend?

4 Wall Street analysts forecast a $94.75 price target for Gilead Sciences (GILD) this month, up 7.18% from its last price of $88.4. Compared to the last 3 and 12 months, the average price target increased by 1.67% and decreased by -4.38%, respectively.

What are Gilead Sciences's analysts' financial forecasts?

Gilead Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $27.23B (high $27.55B, low $27B), average EBITDA is $7.43B (high $7.66B, low $7.23B), average net income is $6.1B (high $6.6B, low $5.39B), average SG&A $5.38B (high $5.66B, low $5.12B), and average EPS is $3.35 (high $3.81, low $2.72). GILD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.29B (high $29.16B, low $27.59B), average EBITDA is $9.23B (high $9.51B, low $9B), average net income is $9.64B (high $10.07B, low $9.3B), average SG&A $5.82B (high $6B, low $5.68B), and average EPS is $7.69 (high $8.03, low $7.42).

Did the GILD's actual financial results beat the analysts' financial forecasts?

Based on Gilead Sciences's last annual report (Dec 2023), the company's revenue was $27.12B, beating the average analysts forecast of $26.7B by 1.56%. Apple's EBITDA was $7.6B, beating the average prediction of $7.21B by 5.55%. The company's net income was $5.66B, missing the average estimation of $6.69B by -15.26%. Apple's SG&A was $6.09B, beating the average forecast of $5.18B by 17.65%. Lastly, the company's EPS was $4.54, missing the average prediction of $6.84 by -33.63%. In terms of the last quarterly report (Dec 2023), Gilead Sciences's revenue was $7.12B, beating the average analysts' forecast of $7.1B by 0.20%. The company's EBITDA was $1.61B, missing the average prediction of $2.32B by -30.39%. Gilead Sciences's net income was $1.43B, missing the average estimation of $2.21B by -35.19%. The company's SG&A was $1.61B, beating the average forecast of $1.46B by 10.09%. Lastly, the company's EPS was $1.15, missing the average prediction of $1.76 by -34.60%